PHILADELPHIA -- For multi-allergen oral immunotherapy (mOIT) patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events (AE) of ...
Researchers uncover why children with asthma or multiple allergies face higher odds of reacting during oral food challenges, and how better screening can make testing safer. Study: Asthma and ...
Hailed for opening a new chapter in food allergy management, oral immunotherapy (OIT) is nevertheless going through growing pains in accessibility and acceptance in clinical practice. In 2020, the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results